NASDAQ:MRVI • US56600D1072
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MARAVAI LIFESCIENCES HLDGS-A (MRVI).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-15 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-13 | Baird | Maintains | Neutral -> Neutral |
| 2025-05-13 | Craig-Hallum | Maintains | Buy -> Buy |
| 2025-03-25 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-03-21 | UBS | Maintains | Neutral -> Neutral |
| 2025-03-03 | B of A Securities | Maintains | Buy -> Buy |
| 2025-02-26 | Baird | Downgrade | Outperform -> Neutral |
| 2024-12-05 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2024-11-14 | Wolfe Research | Initiate | Peer Perform |
| 2024-11-08 | William Blair | Downgrade | Outperform -> Market Perform |
| 2024-11-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-11-08 | Baird | Maintains | Outperform -> Outperform |
| 2024-10-08 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-08-27 | Wells Fargo | Initiate | Overweight |
| 2024-08-16 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-13 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2024-08-08 | UBS | Maintains | Neutral -> Neutral |
| 2024-08-08 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-07-09 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-05-09 | Baird | Maintains | Outperform -> Outperform |
| 2024-04-10 | Craig-Hallum | Initiate | Buy |
| 2024-02-23 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-02-23 | Stifel | Maintains | Buy -> Buy |
| 2023-12-12 | B of A Securities | Upgrade | Neutral -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 288.945M -67.28% | 259.185M -10.30% | 185.743M -28.34% | 208.85M 12.44% | 225.35M 7.90% | 242.11M 7.44% | 257.97M 6.55% | 278.85M 8.09% | 338.32M 21.33% | 380.61M 12.50% | 428.19M 12.50% | |
| EBITDA YoY % growth | 15.072M -97.51% | -22.297M -247.94% | -77.221M -246.33% | 12.213M 115.82% | 18.117M 48.34% | 30.838M 70.22% | 42.534M 37.93% | 47.43M 11.51% | N/A | N/A | N/A | |
| EBIT YoY % growth | -25.182M -104.39% | -70.68M -180.68% | -128.73M -82.13% | -47.182M 63.35% | -27.132M 42.50% | -27.65M -1.91% | N/A | N/A | N/A | N/A | N/A | |
| Operating Margin | -8.72% | -27.27% | -69.31% | -22.59% | -12.04% | -11.42% | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | 0.03 -98.33% | -0.10 -433.33% | -0.28 -180.00% | -0.19 33.57% | -0.14 22.58% | -0.09 34.13% | -0.17 -77.42% | -0.15 9.09% | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.05 40.93% | -0.05 42.75% | -0.05 35.26% | -0.04 -7.10% | -0.03 46.04% | -0.04 10.91% | -0.05 11.38% | -0.04 16.67% |
| Revenue Q2Q % growth | 53.969M 15.20% | 53.792M 13.49% | 48.776M 17.17% | 54.434M 9.16% | 61.822M 14.55% | 54.794M 1.86% | 49.536M 1.56% | 58.293M 7.09% |
| EBITDA Q2Q % growth | 3.101M 112.92% | 3.254M 132.71% | -271.32K -105.01% | 3.815M -86.84% | 8.237M 165.62% | 2.392M -26.49% | -66.3K 75.56% | 3.601M -5.61% |
| EBIT Q2Q % growth | -14.528M 60.44% | -12.097M 66.24% | -14.07M 58.18% | -9.339M 58.55% | -4.605M 68.30% | -10.358M 14.38% | -12.623M 10.29% | -8.92M 4.49% |
All data in USD
17 analysts have analysed MRVI and the average price target is 4.01 USD. This implies a price increase of 31.17% is expected in the next year compared to the current price of 3.055.
MARAVAI LIFESCIENCES HLDGS-A (MRVI) will report earnings on 2026-05-11, after the market close.
The consensus EPS estimate for the next earnings of MARAVAI LIFESCIENCES HLDGS-A (MRVI) is -0.05 USD and the consensus revenue estimate is 53.97M USD.
The number of analysts covering MARAVAI LIFESCIENCES HLDGS-A (MRVI) is 17.